Home › Therapeutic areas › Oncology › Small Cell Lung Cancer
Small Cell Lung Cancer (9 companies)
Companies with an active program in Small Cell Lung Cancer.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ACRV | Acrivon Therapeutics | GI/HepatologyOncology Rare | 1 | Phase 2 | $61.4M | 9 |
| AKTS | Aktis Oncology | Oncology | 1 | Phase 1 | $910M | 10 |
| ALLO | Allogene Therapeutics | ImmunologyOncology Rare | 1 | Phase 2 | $256M | 10 |
| CMPX | Compass Therapeutics | Oncology | 1 | Phase 2 | $109M | 15 |
| GNLX | Genelux | Oncology | 1 | Phase 3 | $96.1M | 3 |
| IDYA | IDEAYA Biosciences | Oncology | 2 | NDA Submitted | $2.65B | 15 |
| LEGN | Legend Biotech | Oncology Rare | 1 | Approved | $3.12B | 17 |
| MAIA | MAIA Biotechnology | Oncology | 1 | Phase 3 | $77.2M | 8 |
| ZYME | Zymeworks | OncologyRespiratory | 1 | Approved | $1.78B | 12 |
No companies match.